Citigroup Maintains Buy on Arcturus Therapeutics, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) and increased the price target from $40 to $48.
February 08, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has reaffirmed its Buy rating on Arcturus Therapeutics and raised the price target from $40 to $48.
The upgrade in price target by a reputable analyst like Yigal Nochomovitz from Citigroup is a strong positive signal for investors, indicating a bullish outlook on the stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100